GlassScriptPhysician profile
Amy L Scott
NPI 1780889766
$1,969.36
in general payments reported to CMS, 2019-2025
30 companies · $398 in 2025
The $398 reported for 2025 was more than what 75% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $378 · 2020: $107 · 2021: $403 · 2022: $139 · 2023: $158 · 2024: $386 · 2025: $398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $942.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $942.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $441.79 | 2019-2025 | |
| Organon LLC | $163.80 | 2021-2025 | Nexplanon, Jada System |
| Hologic Sales and Service, LLC | $156.54 | 2022-2025 | Novasure, Sonata Sonography-Guided Transcervical Fibroid Ablation System, Fluent Fluid Management System |
| Astellas Pharma US INC | $144.32 | 2023-2025 | Veozah |
| Exeltis, USA INC. | $133.38 | 2021-2025 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $112.40 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $108.07 | 2022-2025 | |
| Pfizer INC. | $86.91 | 2019-2023 | |
| Baxter Healthcare | $83.01 | 2024 | Perclot |
| Millicent US INC | $61.71 | 2025 | Intrarosa, Femlyv |
| Minerva Surgical, INC | $49.14 | 2024 | |
| Covidien LP | $44.19 | 2019 | |
| Merck Sharp & Dohme LLC | $43.90 | 2019 | |
| Myovant Sciences INC. | $36.70 | 2021-2022 | |
| Roche Diagnostics Corporation | $32.64 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $26.02 | 2019 | |
| Biogen, INC. | $25.47 | 2025 | Zurzuvae |
| Amag Pharmaceuticals, INC. | $24.77 | 2019-2020 | |
| Allergan, INC. | $23.59 | 2019-2020 | |
| Medtronic, INC. | $22.75 | 2024 | Ligasure |
| Janssen Pharmaceuticals, INC | $19.46 | 2024 | Spravato |
| Meditrina | $18.33 | 2023 | |
| Avanos Medical | $17.84 | 2019 | |
| Abbott Laboratories | $15.86 | 2023 | I-Stat |
| Mylan Pharmaceuticals INC. | $15.29 | 2021 | |
| Sumitomo Pharma America, INC. | $13.71 | 2025 | Myfembree |
| Convatec INC. | $12.79 | 2019 | |
| Amgen INC. | $12.09 | 2022 | |
| Agile Therapeutics, INC. | $11.73 | 2022 | |
| Evofem Biosciences, INC. | $11.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.